HLB Group saw 8 Korean stocks hit upper trading limits on the afternoon of the 15th on the KOSDAQ market after the company announced resolution of key FDA manufacturing facility issues that previously blocked approval of liver cancer drug rivoceranib. The surge followed news that HLB's U.S. subsidiary Eleva Therapeutics received an FDA cGMP inspection conclusion letter on the 14th (local time) from partner Hangzhou Pharmaceuticals, with the FDA classifying the inspection as VAI (Voluntary Action Indicated). The FDA had previously issued a Complete Response Letter (CRL) on the 10th citing manufacturing facility concerns, causing HLB stocks to plunge to lower limits for two consecutive days. The regulatory background involves rivoceranib's pending FDA approval for liver cancer treatment, with manufacturing compliance serving as a critical approval prerequisite.
According to the Korea Exchange, HLB (028300) traded at 34,700 won on the 15th afternoon, up 8,000 won (29.96%) from the previous trading day, reaching the price limit. Major subsidiaries within the group also surged simultaneously. HLB Innovation (024850) (+30.00%), HLB Pharmaceutical (047920) (+30.00%), and HLB Therapeutics (+30.00%) all recorded upper limits. HLB Pep (+29.97%), HLB Biostep (+29.86%), and HLB Life Science (+29.82%) — all KOSDAQ-listed group stocks — also halted trading at upper limits. HLB Global (003580), listed on the Korea Composite Stock Price Index (KOSPI), joined the upper limit lineup with a 29.99% surge to 1,439 won. This represents 8 single-group stocks simultaneously reaching upper limits.
FDA Classifies Hangzhou Pharmaceuticals Facility Inspection as VAI
Eleva Therapeutics announced on the 14th (local time) that it received an FDA cGMP inspection conclusion letter from partner Hangzhou Pharmaceuticals regarding the rivoceranib active pharmaceutical ingredient manufacturing facility. The FDA determined that Hangzhou Pharmaceuticals' manufacturing facility generally complies with current cGMP standards and classified the inspection result as Voluntary Action Indicated (VAI). VAI classification means the manufacturing facility no longer negatively impacts evaluation of new drug approval applications associated with that facility.
The FDA's CRL issued on the 10th cited Hangzhou Pharmaceuticals' active pharmaceutical ingredient manufacturing facility general cGMP inspection results as one of the primary reasons for the letter. The market interprets this VAI final confirmation as a signal that the biggest uncertainty in the drug approval process — manufacturing facility issues pointed out by the FDA — has been resolved.
HLB Plans Expedited Approval Process Following Inspection Conclusion
HLB stated it will expedite the drug approval process based on this inspection conclusion. A company official said the FDA concluded its review of camrelizumab-related supplementary matters requested in the previous CRL without special issues. The official explained that with the active pharmaceutical ingredient manufacturing facility inspection also concluded as VAI, most core issues that were problematic in the drug approval process have been resolved. An HLB official stated, "Since CRL reasons have been essentially immediately resolved, we plan to concentrate all capabilities so that rivoceranib's drug approval process can resume as soon as possible through rapid formal inquiries and close consultation with the FDA."
FAQ
What did HLB Group announce on the 14th regarding FDA inspection?
HLB's U.S. subsidiary Eleva Therapeutics announced on the 14th (local time) that it received an FDA cGMP inspection conclusion letter from partner Hangzhou Pharmaceuticals, with the FDA classifying the rivoceranib active pharmaceutical ingredient manufacturing facility inspection as VAI (Voluntary Action Indicated).
Why did HLB stocks previously hit lower limits on the 10th?
HLB stocks plunged to lower limits for two consecutive days after the company received a Complete Response Letter (CRL) from the FDA on the 10th, with one primary reason being Hangzhou Pharmaceuticals' active pharmaceutical ingredient manufacturing facility general cGMP inspection results.
How many HLB Group stocks reached upper trading limits on the 15th?
8 HLB Group stocks reached upper trading limits on the 15th, including HLB (034700 won, +29.96%), HLB Innovation (+30.00%), HLB Pharmaceutical (+30.00%), HLB Therapeutics (+30.00%), HLB Pep (+29.97%), HLB Biostep (+29.86%), HLB Life Science (+29.82%), and HLB Global (1,439 won, +29.99%).
